Current Urology Reports

, Volume 12, Issue 3, pp 237–242

Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity

  • Johnny Kao
  • Jamie A. Cesaretti
  • Nelson N. Stone
  • Richard G. Stock

DOI: 10.1007/s11934-011-0183-3

Cite this article as:
Kao, J., Cesaretti, J.A., Stone, N.N. et al. Curr Urol Rep (2011) 12: 237. doi:10.1007/s11934-011-0183-3


Current research in prostate brachytherapy focuses on five key concepts covered in this review. Transrectal ultrasound-guided prostate brachytherapy assisted by intraoperative treatment planning is the most advanced form of image-guided radiation delivery. Prostate brachytherapy alone for low-risk prostate cancer achieves lower prostate-specific antigen (PSA) nadirs than intensity-modulated radiotherapy (IMRT) or protons while maintaining durable biochemical control in about 90% of patients without late failures seen in surgically treated patients. As an organ-conserving treatment option, seed implant results in a lower rate of erectile dysfunction and urinary incontinence than surgery that has been validated in several recent prospective studies. Combined IMRT and seed implant has emerged as a rational and highly effective approach to radiation-dose escalation for intermediate- and high-risk prostate cancer. Preliminary results suggest that seed implantation may play a role in improving outcomes for historically poor-prognosis locally advanced and recurrent prostate cancers.


Prostate cancer Brachytherapy Seed implantation Quality of life 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Johnny Kao
    • 1
  • Jamie A. Cesaretti
    • 2
  • Nelson N. Stone
    • 3
  • Richard G. Stock
    • 4
  1. 1.Florida Cancer Physicians NetworkFlorida Radiation Oncology GroupBrandonUSA
  2. 2.Florida Radiation Oncology GroupJacksonvilleUSA
  3. 3.Mount Sinai School of MedicineNew YorkUSA
  4. 4.Mount Sinai School of MedicineNew YorkUSA

Personalised recommendations